194 related articles for article (PubMed ID: 12435521)
41. Late evolution of kidney transplants in elderly donors and recipients receiving initial immunosuppressant treatment with daclizumab, mycophenolate mofetil, and delayed introduction of tacrolimus.
González-Roncero FM; Gentil-Govantes MÁ; González-Molina M; Rivero M; Cantarell C; Alarcón A; Franco A; Sánchez-Plumed J; Lampreabe I; Lauzurica R; González E; Romero R; Ruiz-San Millán JC; Osuna A
Nefrologia; 2012 Jul; 32(4):446-54. PubMed ID: 22806279
[TBL] [Abstract][Full Text] [Related]
42. A prospective randomized open study in liver transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids.
Otero A; Varo E; de Urbina JO; Martín-Vivaldi R; Cuervas-Mons V; González-Pinto I; Rimola A; Bernardos A; Otero S; Maldonado J; Herrero JI; Barrao E; Domínguez-Granados R
Liver Transpl; 2009 Nov; 15(11):1542-52. PubMed ID: 19877219
[TBL] [Abstract][Full Text] [Related]
43. Delayed introduction of tacrolimus postliver transplant with intravenous mycophenolate mofetil preserves renal function without incurring rejection.
Jain A; Constantinescu S; Maloo M; Mukerji AN; Karachristos A; Lau K; Di Carlo A
Transplantation; 2014 Oct; 98(7):e68-70. PubMed ID: 25285953
[No Abstract] [Full Text] [Related]
44. Therapeutic dose monitoring of mycophenolate mofetil in dermatologic diseases.
Sokumbi O; el-Azhary RA; Langman LJ
J Am Acad Dermatol; 2013 Jan; 68(1):36-40. PubMed ID: 22884445
[TBL] [Abstract][Full Text] [Related]
45. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Lupus; 2015 Dec; 24(14):1520-8. PubMed ID: 26162684
[TBL] [Abstract][Full Text] [Related]
46. Rationale for trials of long-term mycophenolate mofetil therapy for primary biliary cirrhosis.
Jones EA
Hepatology; 2002 Feb; 35(2):258-62. PubMed ID: 11826397
[No Abstract] [Full Text] [Related]
47. Long-term dosing patterns of enteric-coated mycophenolate sodium or mycophenolate mofetil with tacrolimus after renal transplantation.
Langone A; Shihab F; Pankewycz O; Doria C; Wiland A; McCague K; Chan L
Clin Transplant; 2014 Sep; 28(9):961-7. PubMed ID: 24893821
[TBL] [Abstract][Full Text] [Related]
48. Effects of tacrolimus, mycophenolate mofetil, and cyclosporine microemulsion on rejection incidence in synchronous pancreas-kidney transplantation.
Bruce DS; Woodle ES; Newell KA; Millis JM; Cronin DC; Loss GE; Pellar S; Josephson MA; Thistlethwaite JR
Transplant Proc; 1998 Mar; 30(2):507-8. PubMed ID: 9532150
[No Abstract] [Full Text] [Related]
49. [Immunosuppressive drug monitoring of cyclosporine, tacrolimus, and mycophenolate mofetil in renal transplantation].
Uchida K
Nihon Jinzo Gakkai Shi; 2005; 47(4):423-9. PubMed ID: 15971884
[No Abstract] [Full Text] [Related]
50. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study.
Claes K; Meier-Kriesche HU; Schold JD; Vanrenterghem Y; Halloran PF; Ekberg H
Nephrol Dial Transplant; 2012 Feb; 27(2):850-7. PubMed ID: 21617197
[TBL] [Abstract][Full Text] [Related]
51. Combination therapy with tacrolimus and betamethasone for a patient with X-linked auto-immune enteropathy.
Kobayashi I; Nakanishi M; Okano M; Sakiyama Y; Matsumoto S
Eur J Pediatr; 1995 Jul; 154(7):594-5. PubMed ID: 7556338
[No Abstract] [Full Text] [Related]
52. Randomized trial of mycophenolate mofetil versus enteric-coated mycophenolate sodium in primary renal transplantation with tacrolimus and steroid avoidance: four-year analysis.
Ciancio G; Gaynor JJ; Zarak A; Sageshima J; Guerra G; Roth D; Brown R; Kupin W; Chen L; Tueros L; Hanson L; Ruiz P; Burke GW
Transplantation; 2011 Jun; 91(11):1198-205. PubMed ID: 21107305
[TBL] [Abstract][Full Text] [Related]
53. Drug Survival Studies in Dermatology:Principles, Purposes, and Pitfalls.
van den Reek JMPA; Kievit W; Gniadecki R; Goeman JJ; Zweegers J; van de Kerkhof PCM; Seyger MMB; de Jong EMGJ
J Invest Dermatol; 2015 Jul; 135(7):1-5. PubMed ID: 26066896
[No Abstract] [Full Text] [Related]
54. Mycophenolate mofetil and leflunomide: promising compounds for the treatment of skin diseases.
Frieling U; Luger TA
Clin Exp Dermatol; 2002 Oct; 27(7):562-70. PubMed ID: 12464151
[TBL] [Abstract][Full Text] [Related]
55. Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept.
Ringe B; Braun F; Lorf T; Canelo R; Schütz E; Sattler B; Ramadori G
Transplant Proc; 1998 Jun; 30(4):1415-6. PubMed ID: 9636573
[No Abstract] [Full Text] [Related]
56. Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.
de Winter BC; Mathot RA; Sombogaard F; Neumann I; van Hest RM; Doorduijn JK; van Gelder T
Ther Drug Monit; 2010 Oct; 32(5):606-14. PubMed ID: 20720518
[TBL] [Abstract][Full Text] [Related]
57. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study.
Boillot O; Seket B; Dumortier J; Pittau G; Boucaud C; Bouffard Y; Scoazec JY
Liver Transpl; 2009 Nov; 15(11):1426-34. PubMed ID: 19877264
[TBL] [Abstract][Full Text] [Related]
58. [Immunosuppressive therapy for nephrotic syndrome and strategy for adverse side effects from that therapy].
Takeda Y; Tomino Y
Nihon Rinsho; 2004 Oct; 62(10):1875-9. PubMed ID: 15500133
[TBL] [Abstract][Full Text] [Related]
59. The use of mycophenolate mofetil for the treatment of autoimmune and chronic idiopathic urticaria: experience in 19 patients.
Zimmerman AB; Berger EM; Elmariah SB; Soter NA
J Am Acad Dermatol; 2012 May; 66(5):767-70. PubMed ID: 21783274
[TBL] [Abstract][Full Text] [Related]
60. Immunosuppressant and cytotoxic drugs: unapproved uses or indications.
Abel EA
Clin Dermatol; 2000; 18(1):95-101. PubMed ID: 10701090
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
